The terms, per the grant. On September 17, 2024, ModernaTX was issued US12090235B2, covering preparation of lipid nanoparticles and methods of administration. The CPC tags — A61K 9/5192, A61K 9/5123, A61K 9/5146 (lipid-particle preparation), plus A61K 45/06 — describe how the particles are made and delivered, not just their composition.
Why process IP is its own layer: in mRNA medicine, knowing what the lipid nanoparticle is (formulation IP) is distinct from knowing how to make and administer it reliably at scale (process IP). Both are protectable, and both can be licensed. Process IP addresses the manufacturing constraint that determines cost and consistency.
The structure point: a deal touching mRNA can carry a formulation license and a separate process license, each with its own royalty. For a model, the process layer is a reusable, infrastructure-style asset whose value scales with manufacturing volume across the platform — distinct from any single program's clinical risk.
What the grant does not promise: a clinical outcome or an approval. It is an exclusivity claim on a manufacturing-and-administration method, valuable to the extent it is adopted across programs.
The takeaway: in an mRNA term teardown, value the process-and-manufacturing IP separately from the formulation, because it is a distinct, reusable royalty layer. Moderna's September 2024 LNP-process grant is a dated example of that manufacturing layer.